Roger Sawhney - 18 Sep 2026 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Reporting relationship: Director
Issuer ticker: ABUS
Reported as of: 18 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Sep 2026, 20:31:17 UTC
Prior SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tuan Nguyen as attorney-in-fact for Roger Sawhney

Key filing fact

Roger Sawhney filed Form 4 for Arbutus Biopharma Corp (ABUS) on 23 Sep 2026.

Key facts

This page summarizes Roger Sawhney's Form 4 filing for Arbutus Biopharma Corp (ABUS).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Sep 2026, 20:31.

Change

Previous filing in this sequence was filed on 10 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001858748 Primary reporting owner

Sawhney Roger

Relationship: Director
Address: C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER
Signature: /s/ Tuan Nguyen as attorney-in-fact for Roger Sawhney
Signature date: 23 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABUS transaction

Common Shares

Options Exercise

Transaction value
Shares: +52,533
Change %
Price: $3.34^*
Shares after: 52,533
Date: 18 Sep 2026
Ownership: Direct

ABUS transaction

Common Shares

Options Exercise

Transaction value
Shares: +78,800
Change %: +150%
Price: $4.24^*
Shares after: 131,333
Date: 18 Sep 2026
Ownership: Direct

ABUS transaction

Common Shares

Tax liability

Transaction value
Shares: -100,508
Change %: -77%
Price: $5.07^*
Shares after: 30,825
Date: 18 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABUS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -52,533
Change %: -33%
Price: $0.000000^*
Shares after: 105,067
Date: 18 Sep 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 52,533
Exercise price: $3.34
Footnotes: F2

ABUS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -78,800
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 18 Sep 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 78,800
Exercise price: $4.24
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.

Footnote F2

The option, representing a right to purchase a total of 157,600 shares, vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd and 3rd anniversaries of the August 4, 2025 grant date, subject to the Reporting Person's continuous service as of each vesting date.

Footnote F3

The option, representing a right to purchase a total of 78,800 shares, was fully vested and exercisable as of the June 8, 2026 grant date.